¼¼°èÀÇ °¡Ãà¿ë ¹é½Å ½ÃÀå
Livestock Vaccines
»óǰÄÚµå : 1731834
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 477 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,015,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,045,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ °¡Ãà¿ë ¹é½Å ½ÃÀåÀº 2030³â±îÁö 79¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 59¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ °¡Ãà¿ë ¹é½Å ½ÃÀåÀº 2024-2030³â¿¡ CAGR 5.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 79¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼Ò ¹é½ÅÀº CAGR 3.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¡±Ý ¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °¡Ãà¿ë ¹é½Å ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 15¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.5%¿Í 4.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °¡Ãà¿ë ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°¡Ãà¿ë ¹é½ÅÀÌ ¼¼°è ½Ä·®¾Èº¸¿Í Àμö°øÅëÀü¿°º´ ´ëÀÀ¿¡ ÀÖÀ¸¸ç, Àü·«Àû Á߿伺ÀÌ Ä¿Áö°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°¡Ãà¿ë ¹é½ÅÀº Àü ¼¼°è °øÁߺ¸°Ç, ½Ä·® °ø±Þ ¾ÈÁ¤¼º, ³ó¾÷ ±â¹Ý °æÁ¦ÀÇ °æÁ¦Àû ȸº¹·Â¿¡ ÀÖÀ¸¸ç, Áß¿äÇÑ Åø·Î Àνĵǰí ÀÖ½À´Ï´Ù. ´Ü¹éÁú ¼ö¿ä Áõ°¡, µµ½ÃÈ­, ½Ä»ýȰ ¼±È£µµ º¯È­ µîÀ» ¹è°æÀ¸·Î ÇÑ Ãà»ê¾÷ÀÇ °­È­´Â °¡Ãà Áý´Ü¿¡¼­ dzÅ亴, Àü¿°º´, ½ÅÁ¾ Àü¿°º´ÀÇ À§ÇèÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾Àº ¼Ò, ´ß, µÅÁö, ¿°¼Ò ¹× ±âŸ °¡ÃàÀÇ ÀÌȯÀ²°ú Æó»çÀ²À» ¿¹¹æÇÏ´Â È¿°úÀûÀ̰í È®Àå °¡´ÉÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ ¹æ¹ýÀÔ´Ï´Ù. ±¸Á¦¿ª(FMD), ¾ÆÇÁ¸®Ä«µÅÁö¿­º´(ASF), Á¶·ùµ¶°¨, ºê·ç¼¿¶óº´ µî ±¹°æÀ» ÃÊ¿ùÇÑ µ¿¹° Áúº´ÀÇ À§Çù¿¡ ´ëÀÀÇϱâ À§ÇØ °¢±¹ÀÌ ´ëÀÀÇϰí ÀÖ´Â °¡¿îµ¥, °¡Ãà ¹é½ÅÀº ±¹°¡ Áúº´ ÅðÄ¡ ¹× ºÀ¼â Àü·«¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

°¡Ãà ¹é½ÅÀº µ¿¹°ÀÇ °Ç°­¿¡ Á÷Á¢ÀûÀ¸·Î µµ¿òÀÌ µÉ »Ó¸¸ ¾Æ´Ï¶ó Àΰ£ÀÇ °Ç°­°ú ¹ÙÀÌ¿À º¸¾È¿¡µµ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Àμö°øÅëÀü¿°º´ º´¿øÃ¼´Â Àΰ£¿¡°Ô ¹ß»ýÇÏ´Â ½ÅÁ¾ Àü¿°º´ÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇϸç, ±× Áß »ó´ç¼ö´Â Àß °ü¸®µÇÁö ¾Ê°Å³ª ¹é½ÅÀ» Á¢Á¾ÇÏÁö ¾ÊÀº µ¿¹° Áý´Ü¿¡¼­ ¹ß»ýÇÕ´Ï´Ù. ¹é½Å Á¢Á¾Àº ¼÷ÁÖÀÇ º´¿øÃ¼ º¸À¯·®À» °¨¼Ò½ÃŰ°í °¨¿° Áֱ⸦ Â÷´ÜÇÏ¿© °øÁß º¸°ÇÀ» º¸È£ÇÕ´Ï´Ù. ¶ÇÇÑ ¿¹¹æÁ¢Á¾Àº Ãà»ê¾÷¿¡¼­ Ç×»ýÁ¦ ÀÇÁ¸µµ¸¦ ÁÙÀ̰í, ÇöÀç ¼¼°è º¸°ÇÀÇ Áß¿äÇÑ ¹®Á¦·Î ¿©°ÜÁö´Â Ç×±ÕÁ¦ ³»¼º(AMR)À» ¿ÏÈ­Çϱâ À§ÇÑ Àü ¼¼°èÀÇ ³ë·ÂÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µ¿¹°, Àΰ£, ȯ°æ °Ç°­ÀÇ »óÈ£ ÀÛ¿ëÀ» ÅëÇØ ¹é½ÅÀº ¿øÇコ ÇÁ·¹ÀÓ¿öÅ©ÀÇ Ãʼ®À¸·Î È®°íÇÑ ÀÔÁö¸¦ ´ÙÁö°í ÀÖ½À´Ï´Ù.

°úÇÐÀû Çõ½Å°ú Á¦Á¶ ±â¼úÀº ¹é½Å °³¹ßÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

ºÐÀÚ»ý¹°ÇÐ, À¯ÀüüÇÐ, ¸é¿ªÇÐÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº °¡Ãà ¹é½Å °³¹ß¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, º¸´Ù Á¤È®Çϰí, ºü¸£°í, È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ DNA ±â¼ú, ¾Æ´ÜÀ§ ¹é½Å, º¤ÅÍ ±â¹Ý Ç÷§Æû, ºñȰ¼ºÈ­ ¹ÙÀÌ·¯½º ¿î¹Ýü´Â º´¿ø¼º º¹±Í ¹× ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÎ º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ¹é½ÅÀ» °³¹ßÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº ƯÁ¤ Ç׿øÀ» Ç¥ÀûÀ¸·Î »ï°í ´Ù¸¥ Á¾À̳ª º´¿øÃ¼ ±ÕÁÖ¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» Á¶ÀýÇÒ ¼ö ÀÖ½À´Ï´Ù. Àΰ£ mRNA ¹é½ÅÀÇ ¼º°øÀ» º»¶á RNA ±â¹Ý ¹é½Å°ú À¯ÀüÀÚ °á¼Õ ¹é½ÅÀº ÇöÀç À¯Çິ ±Ô¸ðÀÇ °³¹ßÀ» ´õ ºü¸£°Ô ÁøÇàÇϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ¿Í ÇÔ²² ¹é½Å Àü´Þ ±â¼úµµ ºñ¾àÀûÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ³»¿­¼º Á¦Á¦ÀÇ ±â¼ú Çõ½ÅÀ¸·Î ÄݵåüÀÎ ¹°·ù°¡ ¾î·Á¿î ¿ÀÁö³ª ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­µµ ¹é½ÅÀ» º¸´Ù ±¤¹üÀ§ÇÏ°Ô º¸±ÞÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¹«Ä§ ÁÖ»ç±â, °æ±¸ ¹Ì³¢Á¦, °æÇÇ ÆÐÄ¡, ºñ°­ ½ºÇÁ·¹ÀÌ´Â Åõ¿©¸¦ °£¼ÒÈ­ÇÏ°í µ¿¹°ÀÇ ½ºÆ®·¹½º¸¦ ÁÙÀ̱â À§ÇØ ½ÃÇèÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ƯÁ¤ °¡Ã౺À̳ª ¹ßº´¿¡ ¸Â°Ô ¸ÂÃãÈ­µÈ ÀÚ°¡¹é½Åµµ ƯÈ÷ º´¿øÃ¼ º¯À̰¡ ½ÉÇϰųª Áö¿ªÀû dzÅ亴ÀÌ ¸¸¿¬ÇÑ Áö¿ª¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¿¬¼Ó »ý»ê ¶óÀÎ, ¹ÙÀÌ¿À¸®¾×ÅÍ ±â¹Ý Ç׿ø ÇÕ¼º, ¸ðµâ½Ä ÃæÀü ¹× ¸¶¹«¸® Ç÷§Æû µî Á¦Á¶ ¾÷±×·¹À̵尡 È®À强À» Çâ»ó½Ã۰í ÀÏ»óÀûÀÎ ¹é½Å ¹èÆ÷¿Í ±ä±Þ ¹é½Å ¹èÆ÷ ¸ðµÎ¿¡ ´ëÇÑ ¸®µå ŸÀÓÀ» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ¹«¿ª ¾Ð·Â, Ãà»ê °æÁ¦°¡ ½ÃÀå ¹ßÀü¿¡ ¹ÌÄ¡´Â ¿ªÇÒÀº ¹«¾ùÀΰ¡?

°¡Ãà¿ë ¹é½Å ½ÃÀåÀº ±ÔÁ¦ Á¶È­, µ¿¹° À§»ý °¨½Ã, ¹«¿ª ÁÖµµÇü ¹ÙÀÌ¿À¾ÈÀü¼º ÄÄÇöóÀ̾ð½ºÀÇ ¿µÇâÀ» Å©°Ô ¹Þ°í ÀÖÀ¸¸ç, OIE(Çö ¼¼°èµ¿¹°º¸°Ç±â±¸), À¯·´ÀǾàǰû(EMA), ¹Ì±¹ ³ó¹«ºÎ(USDA)¿Í °°Àº ¼öÀÇÇÐ ±ÔÁ¦±â°üÀº ¹é½ÅÀÇ Ç°Áú, À¯È¿¼º, ½ÃÆÇ ÈÄ Á¶»ç¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÆÇ ÈÄ Á¶»ç¿¡ °üÇÑ °¡À̵å¶óÀÎÀ» Á¦°øÇϰí, µ¿¹° º¹Áö¸¦ º¸È£Çϸ鼭 ±â¼ú Çõ½ÅÀ» Áö¿øÇÏ´Â ±¸Á¶È­µÈ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â »õ·Î¿î ¹é½Å Ç÷§Æû, ¹ßº´½Ã Á¶°ÇºÎ ½ÂÀÎ, ±ä±Þ»óȲÀ» À§ÇÑ ½Å¼Ó ½ÂÀÎ µî¿¡ Á¡Á¡ ´õ À¯¿¬ÇÏ°Ô ´ëÀÀÇϰí ÀÖÀ¸¸ç, ÀÌ´Â »ó¾÷È­ °æ·Î¿Í ¹Î°ü Çù·ÂÀ» °¡¼ÓÈ­ÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

±¹Á¦ ¹«¿ª ¿ªÇÐÀº °¡Ãà ¹é½Å Á¢Á¾ÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. »ì¾ÆÀÖ´Â °¡Ãà, À°·ù ¹× À¯Á¦Ç°À» ¼öÃâÇÏ´Â ±¹°¡´Â ¾ö°ÝÇÑ µ¿¹° À§»ý Áõ¸í ¹× ¹«º´ ¼±¾ðÀ» µû¶ó¾ß Çϸç, ÀÌ·¯ÇÑ Áõ¸íÀº È¿°úÀûÀÎ ¹é½Å Á¢Á¾ ÇÁ·ÎÅäÄÝ¿¡ ´Þ·Á ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹é½Å Á¢Á¾ À¯¹«¿¡ °ü°è¾øÀÌ FMD ûÁ¤±¹ ÁöÀ§´Â °íºÎ°¡°¡Ä¡ ¼öÃâ ½ÃÀå¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¿ìÇÕ´Ï´Ù. ¹é½Å Á¢Á¾ Áؼö ¿©ºÎ´Â º¸Á¶±Ý, °¡Ãà º¸Çè, °¡Ãà À̵¿ Çã°¡Áõ ȹµæ¿¡µµ ÇʼöÀûÀÔ´Ï´Ù. »ý»êÀÚ Â÷¿ø¿¡¼­´Â »ç·áºñ, ±âÈÄ º¯È­, ½ÃÀå º¯µ¿°ú °ü·ÃµÈ °æÁ¦Àû ¾Ð·ÂÀ¸·Î ÀÎÇØ ¹é½Å Á¢Á¾À» ÅëÇÑ Áúº´ ¿¹¹æÀÌ Ä¡·á³ª µµÅ¿¡ ±â¹ÝÇÑ Á¢±Ù ¹æ½Äº¸´Ù ´õ ¸Å·ÂÀûÀÔ´Ï´Ù.

Àü ¼¼°è °¡Ãà ¹é½Å ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀº?

°¡Ãà ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ °Å½Ã°æÁ¦Àû, ±â¼úÀû, Á¤Ã¥Àû ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå µÎµå·¯Áø ÃËÁø¿äÀÎ Áß Çϳª´Â ´Ü¹éÁúÀÌ Ç³ºÎÇÑ ½Ä½À°ü°ú Áý¾àÀû Ãà»êÀ¸·Î ¼¼°è ½Ä·® ½Ã½ºÅÛÀÇ ±¸Á¶Àû ÀüȯÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀüȯÀº ƯÈ÷ ¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä«, ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç, ¼Òµæ Áõ°¡¿Í µµ½ÃÈ­·Î ÀÎÇØ °¡±Ý·ù, ¼Ò°í±â, À¯Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä¿¡ Áö¼ÓÀûÀ¸·Î ´ëÀÀÇϱâ À§ÇØ »ý»êÀÚµéÀº Æó»çÀ²À» ÁÙÀ̰í, »ç·á È¿À²À» ³ôÀ̸ç, Àüü °¡ÃàÀÇ »ý»ê¼ºÀ» Çâ»ó½ÃŰ´Â ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â Á¤ºÎ ÁÖµµÀÇ Áý´Ü ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥, Àü¿°º´ ´ëÀÀ Àü·«, ±âºÎÀÚ Áö¿øÀ» ÅëÇÑ ¼öÀÇ»ç Áö¿ø µîÀÌ ¹é½Å Á¢Á¾·ü°ú ¼ö¿ä¸¦ ´õ¿í È®´ëÇϰí ÀÖÀ¸¸ç, FAO¿Í ¼¼°èÀºÇà°ú °°Àº ±â°üµéÀÇ ¼öÀÇÇÐ ÀÎÇÁ¶ó ¹× Áúº´ °¨½Ã ½Ã½ºÅÛ ±¸Ãà ³ë·Âµµ ¹é½Å µµÀÔ¿¡ ´ëÇÑ Áö¿ªÀû Áغñ ż¼¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¹é½Å µµÀÔÀ» À§ÇÑ Áö¿ªÀû Áغñ ż¼¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ µ¿¹° À§»ý Ç÷§ÆûÀº ¹é½Å ÃßÀû, ºÎÀÛ¿ë º¸°í, ÄݵåüÀÎ ¸ð´ÏÅ͸µÀ» Áö¿øÇϸç, ¸ð¹ÙÀÏ ±â¹Ý °¡Ãà À§»ý ¼­ºñ½º´Â ¼Ò³ó°ú À¯¸ñ¹ÎÀ» ´ë»óÀ¸·Î ÇÑ ¾Æ¿ô¸®Ä¡ ¼­ºñ½º¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

¹Î°£ ºÎ¹®ÀÇ Âü¿©µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´Ù±¹Àû Á¦¾à»çÀÇ µ¿¹° À§»ý ºÎ¹®Àº ¹é½Å Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí, ÇöÁö Á¦Á¶¾÷ü¸¦ ÀμöÇϰí, Áö¿ª R&D ¼¾ÅÍ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ÇÕ¼º»ý¹°ÇÐ ¹× ¹Ì»ý¹°À» ÀÌ¿ëÇÑ ¹é½Å °ü·Ã ½ºÅ¸Æ®¾÷ÀÇ È°µ¿ÀÌ È°¹ßÇØÁö¸é¼­ Á¾ ƯÀÌÀûÀ̰í Á¤¹ÐÇÑ ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ »õ·Î¿î ÁöÆòÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÈûµéÀÇ Áö¼ÓÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ¼¼°è °¡Ãà ¹é½Å ½ÃÀåÀº ±Ô¸ð»Ó¸¸ ¾Æ´Ï¶ó Àü·«Àû ¿¬°ü¼º¿¡¼­µµ ¼ºÀåÇÏ¿© µ¿¹°ÀÇ »ý»ê¼º, °æÁ¦ ȸº¹·Â, °øÁß º¸°ÇÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

¹é½Å À¯Çü(¼Ò ¹é½Å, °¡±Ý ¹é½Å, µÅÁö ¹é½Å, ±âŸ ¹é½Å À¯Çü), ±â¼ú(»ý¹é½Å ±â¼ú, ºÒȰȭ ¹é½Å ±â¼ú, À¯ÀüÀÚÀçÁ¶ÇÕ ¹é½Å ±â¼ú, ±âŸ ±â¼ú), Åõ¿© °æ·Î(°æ±¸Åõ¿© °æ·Î, ºñ°æ±¸Åõ¿© °æ·Î, ±âŸ Åõ¿© °æ·Î), ÃÖÁ¾»ç¿ëÀÚ(µ¿¹°º´¿ø ÃÖÁ¾»ç¿ëÀÚ, µ¿¹°º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ ÇÕ°è 42»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Livestock Vaccines Market to Reach US$7.9 Billion by 2030

The global market for Livestock Vaccines estimated at US$5.9 Billion in the year 2024, is expected to reach US$7.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Bovine Vaccine, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Poultry Vaccine segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 7.6% CAGR

The Livestock Vaccines market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Livestock Vaccines Market - Key Trends & Drivers Summarized

Why Are Livestock Vaccines Gaining Strategic Importance in Global Food Security and Zoonotic Disease Control?

Livestock vaccines are increasingly recognized as critical tools in global public health, food supply stability, and economic resilience in agriculture-based economies. The intensification of animal farming-driven by growing protein demand, urbanization, and shifting dietary preferences-has elevated the risk of endemic, epidemic, and emerging infectious diseases among livestock populations. Vaccination offers an effective, scalable, and often cost-efficient method for preventing morbidity and mortality in cattle, poultry, swine, goats, and other farmed animals. As countries grapple with the threat of transboundary animal diseases such as foot-and-mouth disease (FMD), African swine fever (ASF), avian influenza, and brucellosis, livestock vaccines are becoming integral to national disease eradication and containment strategies.

Beyond direct animal health benefits, livestock vaccines have far-reaching implications for human health and biosecurity. Zoonotic pathogens account for a significant proportion of emerging infectious diseases in humans, many of which originate in poorly managed or unvaccinated animal populations. Vaccination reduces pathogen load in reservoir hosts, interrupting transmission cycles and safeguarding public health. Moreover, immunization reduces reliance on antibiotics in animal husbandry, supporting global efforts to mitigate antimicrobial resistance (AMR), which is now regarded as a critical global health challenge. These intersections between animal, human, and environmental health have cemented vaccines as a cornerstone of the One Health framework.

How Are Scientific Innovations and Manufacturing Technologies Reshaping Vaccine Development?

Rapid advancements in molecular biology, genomics, and immunology are revolutionizing livestock vaccine development, enabling more precise, faster, and scalable solutions. Recombinant DNA technology, subunit vaccines, vector-based platforms, and inactivated virus carriers are being used to develop safer and more effective vaccines with reduced risk of virulence reversion or side effects. These approaches allow for the targeting of specific antigens and the tailoring of immune responses to different species and pathogen strains. RNA-based and gene-deletion vaccines, modeled on human mRNA vaccine success, are under exploration for faster pandemic-scale development.

In parallel, vaccine delivery technologies are improving dramatically. Innovations in thermostable formulations are enabling wider vaccine penetration in remote or infrastructure-poor regions where cold chain logistics are challenging. Needle-free injectors, oral baits, transdermal patches, and intranasal sprays are being piloted to simplify administration and reduce animal stress. Autogenous vaccines-customized for specific herds or outbreaks-are also gaining traction, particularly in regions where pathogens mutate rapidly or are locally endemic. Manufacturing upgrades, including continuous production lines, bioreactor-based antigen synthesis, and modular fill-and-finish platforms, are improving scalability and reducing lead times for both routine and emergency vaccine deployment.

What Role Do Regulatory Frameworks, Trade Pressures, and Livestock Economics Play in Market Evolution?

The livestock vaccines market is strongly influenced by regulatory harmonization, animal health surveillance, and trade-driven biosafety compliance. Veterinary regulatory agencies, including the OIE (now WOAH), EMA, and USDA, provide guidelines for vaccine quality, efficacy, and post-market surveillance, creating a structured environment that supports innovation while safeguarding animal welfare. Regulatory frameworks are increasingly accommodating novel vaccine platforms, conditional licensure during outbreaks, and fast-track approval for emergency situations-factors that are accelerating commercialization pathways and public-private collaborations.

International trade dynamics further amplify the importance of livestock vaccination. Countries exporting live animals, meat, or dairy products must comply with stringent animal health certifications and disease-free declarations, which hinge on effective immunization protocols. For instance, FMD-free status with or without vaccination determines market access to high-value export markets. Vaccine compliance is also critical in obtaining subsidies, livestock insurance, and access to livestock movement permits. At the producer level, economic pressures related to feed costs, climate variability, and market volatility are making disease prevention through vaccination more attractive than curative or culling-based approaches.

What Is Fueling Global Expansion of the Livestock Vaccines Market?

The growth in the livestock vaccines market is driven by several converging macroeconomic, technological, and policy factors. One of the most prominent drivers is the structural shift in global food systems toward protein-rich diets and intensive animal farming. This transition is particularly visible in Asia, Latin America, and parts of Africa, where rising incomes and urbanization are spurring demand for poultry, beef, and dairy products. To meet these demands sustainably, producers are investing in vaccination programs that reduce mortality, enhance feed efficiency, and improve overall herd productivity.

Government-sponsored mass vaccination programs, pandemic preparedness strategies, and donor-supported veterinary outreach in low- and middle-income countries are further expanding vaccine coverage and demand. Initiatives by organizations such as the FAO and World Bank to build veterinary infrastructure and disease monitoring systems are also increasing regional readiness for vaccine adoption. Digital animal health platforms are supporting vaccine tracking, adverse event reporting, and cold chain monitoring, while mobile-based livestock health services are improving outreach to smallholders and nomadic pastoralists.

Private sector engagement is also rising. Animal health divisions of multinational pharmaceutical firms are expanding vaccine portfolios, acquiring local manufacturers, and investing in regional R&D centers. In parallel, startup activity around synthetic biology and microbiome-enhanced vaccines is opening new frontiers in species-specific and precision immunization. As these forces continue to interact, the global livestock vaccines market is poised to grow not only in size but in strategic relevance, securing animal productivity, economic resilience, and public health security alike.

SCOPE OF STUDY:

The report analyzes the Livestock Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Bovine Vaccine, Poultry Vaccine, Porcine Vaccine, Other Vaccine Types); Technology (Live Attenuated Vaccine Technology, Inactivated Vaccine Technology, Recombinant Vaccine Technology, Other Technologies); Administration Route (Oral Administration Route, Parenteral Administration Route, Other Routes of Administration); End-User (Veterinary Hospitals End-User, Veterinary Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â